Your session is about to expire
← Back to Search
Repurposed Medications for COVID-19
Study Summary
This trial is testing whether repurposed drugs can help relieve symptoms in people with mild to moderate COVID-19. People will either get the drugs or a placebo, and report any new or worsening symptoms. The trial is mostly remote, but some people may need in-person visits.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Media Library
- I am 30 years old or older.I have been in the hospital recently or am currently hospitalized.I am 30 years old or older.I am not allergic or unable to take the study drug due to other medications I'm on.I've had symptoms like fever, cough, or body aches for less than a week.I was diagnosed with COVID-19 more than 10 days ago.I have had symptoms like fever, cough, or body aches for less than a week.
- Group 1: Arm G - Metformin
- Group 2: Arm G - Placebo
- Group 3: Arm A - Placebo
- Group 4: Arm B - Fluvoxamine
- Group 5: Arm C - Fluticasone
- Group 6: Arm D - Placebo
- Group 7: Arm F - Montelukast
- Group 8: Arm F - Placebo
- Group 9: Arm D - Ivermectin 600
- Group 10: Arm B- Placebo
- Group 11: Arm C - Placebo
- Group 12: Arm E - Placebo
- Group 13: Arm A - Ivermectin 400
- Group 14: Arm E - Fluvoxamine 100
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 7 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 14 null
- Follow Ups: You may be asked to continue sharing information regarding the trial for 120 Months after you stop receiving the treatment.
Frequently Asked Questions
What does Fluvoxamine commonly help with?
"Fluvoxamine is often given to patients suffering from strongyloidiasis, which is caused by strongyloides stercoralis infection. In addition, Fluvoxamine can help treat other conditions such as obsessive-compulsive disorder, sinusitis, and seasonal allergic rhinitis."
Where are the patients being drawn from for this trial?
"There are 94 clinical trial sites participating in this study, including but not limited to: Highlands Medical Associates, P.A. in Highlands, Texas, Health Quality Primary Care in Lawrence, Massachusetts, and Olivo Wellness Medical Center in Chicago, Illinois."
Does fluvoxamine have a history of being studied?
"Fluvoxamine was first studied in 2016 at Milton Keynes University Hospital. So far, there have been 18474 completed studies. 29 trials are still recruiting, many of which are based in Highlands, Texas."
Does Fluvoxamine have a high potential for abuse?
"Fluvoxamine's safety is well-documented, as it has gone through Phase 3 clinical trials. These trials not only test for efficacy, but also repeat testing to confirm safety."
Are we currently able to enroll in this trial?
"That is correct, the online information from clinicaltrials.gov does show that the trial is still looking for participants. The 15000 patients needed for the study are being recruited from 94 different locations, and the trial was first posted on June 8th, 2021."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Lapis Clinical Research: < 24 hours
Average response time
- < 1 Day
Share this study with friends
Copy Link
Messenger